Fourth Quarter 2024 vs. Fourth Quarter 2023 Revenue of $21.8 million compared to $23.5 million;Gross profit of $4.3 million compared to $4.1 ...

Transformational 2024: successfully advanced from preclinical to clinical stage companyStrengthened leadership team to drive growth and advance ...

For the three months ended December 31, 2024, net income increased by 9.9% to $9,164,362 as compared to $8,335,525 for the same period in 2023. Net income for the year ended December 31, 2024 ...

Grew Total Revenue 8% Year-over-Year to $45 Million in the Fourth Quarter 2024 - - Assets Under Management (“AuM”) Increased 13% Year-over-Year ...

A Conference call is scheduled for Tuesday April 1st, 2025, 11:00am Eastern Time See dial in number belowTABER, ALBERTA, March 31, 2025 (GLOBE ...

To accelerate potential completion of ongoing partnership restructuring negotiations, Orchestra BioMed and Terumo have elected to enter a mediation process and are currently working on a procedural ...

Quarterly Adjusted EBITDA of $1.9 Million in Q4, a $4.9 Million Improvement YoY Annual Adjusted EBITDA of $(0.2) Million in 2024, a $12.8 Million ...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple ...

ROSEMONT, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation ("Wintrust") (Nasdaq: WTFC) today announced it will release first quarter 2025 earnings results after the market ...

DETROIT, March 31, 2025 (GLOBE NEWSWIRE) -- Xtreme One Entertainment, Inc. (OTCPink: XONI) today announced its financial results for the full year ending December 31, 2024, details of which have been ...

Issues guidance following a transformative year with the Company adding two new business lines, significantly strengthening ...

Revenue reached $74.67M, exceeding guidance and demonstrating continued strong sales growth and execution ---- Net Income excluding ...